Skip to main content
SpringerLink
Log in

Elektive Strahlentherapie pelviner Lymphknoten beim High-risk-Prostatakarzinom?

Bewertung der Relation zwischen der relativen Risikoreduktion eines PSA-Rezidivs (prostataspezifisches Antigen) innerhalb von 5 Jahren und einem absoluten Überlebensvorteil

Elective radiotherapy of pelvic lymph nodes in high-risk prostate cancer?

Evaluation of the relationship between the relative risk reduction of PSA (prostate-specific antigen) relapse within 5 years and absolute survival benefit

  • Journal Club
  • Published:
Der Urologe Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Incrocci L, Wortel RC, Alemayehu GU et al (2016) Hypofractionated versus conventionally fractionated radiotherapy for patients with localized prostate cancer (HYPRO): final efficacy results from a randomized, multicentre, open-label, phase 3 trial. Lancet Oncol 17:1061–1069

    Article  Google Scholar 

  2. Widmark A, Gunnlaugsson A, Beckman L et al (2019) Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‑year outcomes of the HYPO-RT-PC randomized, non-inferiority, phase 3 trial. Lancet 394:385–395

    Article  Google Scholar 

  3. Kerkmeijer LGW, Groen VH, Pos FJ et al (2021) Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized trial. J Clin Oncol 39:787–796

    Article  Google Scholar 

  4. Xie W, Regan MM, Buyse M et al (2020) Event-free survival, a prostate-specific-antigen-based composite end point, is not a surrogate for overall survival in men with localized prostate cancer treated with radiation. J Clin Oncol 38:3032–3042

    Article  Google Scholar 

  5. Mason MD, Parulekar WR, Sydes MR et al (2015) Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer. J Clin Oncol 33:2143–2150

    Article  Google Scholar 

  6. Widmark A, Klepp O, Solberg A et al (2009) Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomized phase III trial. Lancet 373:301–308

    Article  CAS  Google Scholar 

  7. Mottet N, Peneau M, Mazeron JJ et al (2012) Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomized phase 3 trial. Eur Urol 62:213–219

    Article  Google Scholar 

  8. Early Breast Cancer Trialists’ Collaborative Group (2011) Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10801 women in 17 randomised trials. Lancet 378:1707–1716

    Article  Google Scholar 

  9. Pommier P, Chabaud S, Lagrange JL et al (2007) Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUC-01. J Clin Oncol 25:5366–5373

    Article  Google Scholar 

  10. Roach M, Moughan J, Lawton CAF et al (2018) Sequence of hormonal therapy and radiation field size in unfavourable, localized prostate cancer (NRG/RTOG 9413): long-term results of a randomized, phase 3 trial. Lancet Oncol 19:1504–1515

    Article  Google Scholar 

  11. Alayed Y, Cheung P, Vesprini D et al (2019) SABR in high-risk prostate cancer: outcomes from 2 prospective clinical trials with and without elective nodal irradiation. Int J Radiat Oncol Boil Phys 104:36–41

    Article  Google Scholar 

  12. Calais J, Ceci F, Eiber M et al (2019) 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single.arm, comparative imaging trial. Lancet Oncol 20:1286–1294

    Article  CAS  Google Scholar 

  13. Calais J, Kishan AU, Cao M et al (2018) Potential impact of 68Ga-PSMA-11 PET/CT on the planning of definitive radiation therapy for prostate cancer. J Nucl Med 59:1714–1721

    Article  CAS  Google Scholar 

  14. De Bleser E, Jereczek-Fossa BA, Pasquier D et al (2019) Metastasis-directed therapy in treating nodal oligorecurrent prostate cancer: a multi-institutional analysis comparing the outcome and toxicity of stereotactic body radiotherapy and elective nodal radiotherapy. Eur Urol 76:732–739

    Article  Google Scholar 

  15. Steuber T, Jilg C, Tennstedt P et al (2019) Standard of care versus metastases-directed therapy for PET-detected nodal oligorecurrent prostate cancer following multimodality treatment: a multi-institutional case-control study. Eur Urol Focus 5:1007–1013

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Westdeutsches Tumorzentrum, Strahlenklinik, Universitätsklinikum Essen (AöR), Hufelandstraße 55, 45147, Essen, Deutschland

    M. Stuschke

  2. Urologische Poliklinik, Universitätsklinikum Essen (AöR), Essen, Deutschland

    B. Hadaschik

Authors
  1. M. Stuschke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Hadaschik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Stuschke.

Ethics declarations

Interessenkonflikt

M. Stuschke ist Teilnehmer an Advisory Boards von AstraZeneca, Bristol-Myers Squibb, Sanofi-Aventis und Janssen-Cilag. Institutionelle Unterstützung zur Durchführung einer klinischen Studie durch AstraZeneca. B. Hadaschik gibt an, dass kein Interessenkonflikt besteht.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stuschke, M., Hadaschik, B. Elektive Strahlentherapie pelviner Lymphknoten beim High-risk-Prostatakarzinom?. Urologe 60, 1051–1053 (2021). https://doi.org/10.1007/s00120-021-01543-3

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-021-01543-3

Search

Navigation